MP27-06 DEVELOPMENT OF A NEW PROGNOSTIC MODEL TO PREDICT SURVIVAL OF PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA RECEIVING FIRST-LINE GEMCITABINE PLUS CISPLATIN CHEMOTHERAPY: MULTICENTER RETROSPECTIVE STUDY BY THE SAPPORO MEDICAL UNIVERSITY UROLOGIC ONCOLOGY CONSORTIUM (SUOC)

Abstract

You have accessJournal of UrologyBladder Cancer: Upper Tract Transitional Cell Carcinoma II1 Apr 2016MP27-06 DEVELOPMENT OF A NEW PROGNOSTIC MODEL TO PREDICT SURVIVAL OF PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA RECEIVING FIRST-LINE GEMCITABINE PLUS CISPLATIN CHEMOTHERAPY: MULTICENTER RETROSPECTIVE STUDY BY THE SAPPORO MEDICAL UNIVERSITY UROLOGIC ONCOLOGY CONSORTIUM (SUOC) Takeshi Maehana, Toshiaki Tanaka, Tetsuya Shindo, Atsushi Takahashi, Naoki Ito, Keisuke Taguchi, Hiroshi Hotta, and Naoya Masumori Takeshi MaehanaTakeshi Maehana More articles by this author , Toshiaki TanakaToshiaki Tanaka More articles by this author , Tetsuya ShindoTetsuya Shindo More articles by this author , Atsushi TakahashiAtsushi Takahashi More articles by this author , Naoki ItoNaoki Ito More articles by this author , Keisuke TaguchiKeisuke Taguchi More articles by this author , Hiroshi HottaHiroshi Hotta More articles by this author , and Naoya MasumoriNaoya Masumori More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.1037AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Several studies have shown the impact of systemic inflammation on the prognosis in patients with various types of cancers, including urothelial carcinoma (UC). The aim of this study was to evaluate the prognostic significance of pretreatment inflammatory markers in patients with metastatic UC who underwent first-line gemcitabine plus cisplatin (GC) chemotherapy. METHODS We reviewed the medical records of 214 metastatic UC patients who received first-line GC at 14 institutions between 2005 and 2014. The associations of pretreatment clinical factors, including the neutrophil-to-lymphocyte ratio (NLR), derived NLR, platelet-to-lymphocyte ratio, Onodera's prognostic nutritional index and C-reactive protein (CRP), with progression-free survival (PFS) and overall survival (OS) were assessed. The Cox proportional hazards model was used for multivariate analysis. RESULTS After excluding 27 patients with missing data, 187 patients were finally enrolled. The median PFS and OS were 7.5 months (IQR 3.6-11.9) and 11.7 months (IQR 7.3-19.9), respectively. Multivariate analysis showed that pretreatment CRP ≥ 1.0 mg/dL and liver or bone metastasis were independent poor prognostic factors for PFS and OS (Table). A prognostic model predicting OS was constructed based on the number of these three variables present (0, 1 and 2). The classified patients showed significantly different OS (p < 0.0001, log-rank test, Figure) and Harrell's concordance index was 0.66 (95%CI 0.58 - 0.74). CONCLUSIONS Pretreatment CRP elevation is an independent poor prognostic factor for mUC in patients undergoing first-line GC chemotherapy. Our newly developed prognostic model using the pretreatment CRP is a good discriminator of OS in metastatic UC patients. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e364 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Takeshi Maehana More articles by this author Toshiaki Tanaka More articles by this author Tetsuya Shindo More articles by this author Atsushi Takahashi More articles by this author Naoki Ito More articles by this author Keisuke Taguchi More articles by this author Hiroshi Hotta More articles by this author Naoya Masumori More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...